Essa Pharma Stock Cash Flow From Operations
| EPIX Stock | USD 1.92 0.01 0.52% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess ESSA Pharma's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. ESSA Pharma Company Cash Flow From Operations Analysis
ESSA Pharma's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current ESSA Pharma Cash Flow From Operations | (22.72 M) |
Most of ESSA Pharma's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ESSA Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, ESSA Pharma has (22.72 Million) in Cash Flow From Operations. This is 104.31% lower than that of the Biotechnology sector and 136.33% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 102.34% higher than that of the company.
ESSA Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ESSA Pharma's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ESSA Pharma could also be used in its relative valuation, which is a method of valuing ESSA Pharma by comparing valuation metrics of similar companies.ESSA Pharma is currently under evaluation in cash flow from operations category among its peers.
ESSA Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.16 | ||||
| Current Valuation | (28.91 M) | ||||
| Shares Outstanding | 44.34 M | ||||
| Shares Owned By Insiders | 6.01 % | ||||
| Shares Owned By Institutions | 78.02 % | ||||
| Number Of Shares Shorted | 770.43 K | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 0.75 X | ||||
| EBITDA | (28.45 M) | ||||
| Net Income | (28.54 M) | ||||
| Cash And Equivalents | 174.6 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 329.26 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 43.43 X | ||||
| Book Value Per Share | 2.56 X | ||||
| Cash Flow From Operations | (22.72 M) | ||||
| Short Ratio | 1.82 X | ||||
| Earnings Per Share | (0.64) X | ||||
| Target Price | 1.74 | ||||
| Number Of Employees | 35 | ||||
| Beta | 1.56 | ||||
| Market Capitalization | 84.69 M | ||||
| Total Asset | 128.11 M | ||||
| Retained Earnings | (208 M) | ||||
| Working Capital | 124.26 M | ||||
| Current Asset | 10.02 M | ||||
| Current Liabilities | 3.63 M | ||||
| Net Asset | 128.11 M |
About ESSA Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ESSA Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ESSA Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ESSA Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.